Logo

American Heart Association

  11
  0


Final ID: Mo3064

Prognostic Value of Systolic Blood Pressure One Year After An Acute Coronary Syndrome: Insights from the SPUM-ACS Cohort

Abstract Body (Do not enter title and authors here): Background
Current US and European guidelines recommend targeting a systolic blood pressure (SBP) below 130 mmHg in patients at high cardiovascular (CV) risk, such as those with a history of acute coronary syndrome (ACS), though these recommendations are largely extrapolated from trials in the general hypertensive population.

Aims
Our aim was to evaluate the prognostic significance of SBP measured one year after an ACS event on subsequent CV outcomes.

Methods
The SPUM-ACS cohort prospectively enrolled patients with ACS between 2009 and 2017 across four Swiss tertiary care centers. We included patients who were alive at one-year post-enrollment and had available SBP measurements at that time point. The association between continuous SBP, measured one year post ACS (marking the start of the follow-up period) and the risk of the composite outcome of 3-point major adverse CV events (MACE) —including CV death, non-fatal stroke or transient ischemic stroke, and non-fatal myocardial infarction—was assessed using restricted cubic spline modeling. Outcomes were monitored up to five years after the index ACS event. Analyses were adjusted for age, sex, established CV risk factors and antihypertensive medication classes.

Results
A total of 2,731 patients (mean age 63±12 years; 82% male; mean SBP 132±19 mmHg; 55.1% ST elevation myocardial infarction) were included in the analysis. During a median follow-up of 4.0 years, 273 patients experienced a MACE. The association between SBP at 1 year and the risk of 3-point MACE demonstrated a nonlinear, J-shaped pattern (Figure 1, Pnon-linearity=0.05) The lowest risk was observed for SBP values between ~125 and 135 mmHg (23.7% of the cohort), with a progressive increase in risk for SBP levels above 135 mmHg (40.4% of the cohort). Specifically, for SBP values above 135 mmHg, each 5 mmHg-increase was associated with a higher risk of MACE (adjusted hazard ratio: 1.09; 95% confidence interval: 1.01–1.18). In analyses stratified by age and sex, the J-shaped relationship remained consistent, with no significant interaction observed (Pinteraction for age=0.80; Pinteraction for sex=0.66; Figure 2).


Conclusions
In this large and well-characterized cohort of post-ACS patients, the lowest risk of CV events was observed with SBP levels between ~125 and 135 mmHg, without evidence of differences by age and sex. Our data support the recommendations of targeting SBP within a reasonable range after an ACS while avoiding both over- and undertreatment.
  • Lu, Henri  ( Lausanne University Hospital , Lausanne , Switzerland )
  • Räber, Lorenz  ( Bern University Hospital , Bern , Switzerland )
  • Muller, Olivier  ( Lausanne University Hospital , Lausanne , Switzerland )
  • Rodondi, Nicolas  ( Bern University Hospital , Bern , Switzerland )
  • Mach, Francois  ( Geneva University Hospital , Geneva , Switzerland )
  • Gencer, Baris  ( Lausanne University Hospital , Lausanne , Switzerland )
  • Follonier, Cedric  ( Geneva University Hospital , Geneva , Switzerland )
  • Artels, Louise  ( Lausanne University Hospital , Lausanne , Switzerland )
  • Skali, Hicham  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Desai, Akshay  ( BRIGHAM WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Carballo, David  ( Geneva University Hospital , Geneva , Switzerland )
  • Nanchen, David  ( Lausanne University Hospital , Lausanne , Switzerland )
  • Luscher, Thomas  ( Center for Molecular Cardiology , Schlieren , Switzerland )
  • Matter, Christian  ( Universitatsspital Zurich , Zurich , Switzerland )
  • Author Disclosures:
    Henri Lu: DO have relevant financial relationships ; Consultant:Cytokinetics:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Advisor:Bayer:Past (completed) | Lorenz Räber: No Answer | olivier muller: No Answer | Nicolas Rodondi: No Answer | Francois Mach: No Answer | Baris Gencer: No Answer | Cedric Follonier: No Answer | Louise Artels: DO NOT have relevant financial relationships | Hicham Skali: DO have relevant financial relationships ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now) | Akshay Desai: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Past (completed) ; Consultant:River2Renal:Active (exists now) ; Consultant:Roche:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Novartis:Past (completed) ; Consultant:Merck:Past (completed) ; Consultant:Medtronic:Past (completed) ; Consultant:Medpace:Active (exists now) ; Consultant:GlaxoSmithKline:Past (completed) ; Consultant:Endotronix:Active (exists now) ; Consultant:CVS:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Researcher:Biofourmis:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Axon Therapies:Past (completed) ; Consultant:Avidity Biopharma:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Alnylam:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Past (completed) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) | David Carballo: No Answer | David Nanchen: DO NOT have relevant financial relationships | Thomas Luscher: No Answer | Christian Matter: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Novel Biomarkers, Indices & Blood-Pressure Targets in Stable CAD

Monday, 11/10/2025 , 01:00PM - 02:00PM

Abstract Poster Board Session

More abstracts on this topic:
A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial

May Heidi, Colipi Dominique, Whiting Tyler, Muhlestein Joseph, Le Viet, Anderson Jeffrey, Babcock Daniel, Wayman Libby, Bair Tami, Knight Stacey, Knowlton Kirk, Iverson Leslie

A Personal Risk Assessment Device in Patients with Chest Pain

Shvilkin Alexei, Zlatic Natasa, Atanasoski Vladimir, Grujovic Zdolsek Sanja, Popovic Maneski Lana, Miletic Marjan, Vukcevic Vladan

More abstracts from these authors:
Systolic Blood Pressure in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pooled Participant-Level Analysis of 4 Large-Scale Trials

Lu Henri, Pfeffer Marc, Pitt Bertram, Zannad Faiez, Zile Michael, Mcmurray John, Solomon Scott, Desai Akshay, Kondo Toru, Claggett Brian, Vaduganathan Muthiah, Neuen Brendon, Beldhuis Iris, Jhund Pardeep, Mc Causland Finnian, Anand Inder

The Association of Cardiac Structure and Function with Incident Stroke in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT and PARAGON-HF Trials

Hamatani Yasuhiro, Desai Akshay, Shah Amil, Hegde Sheila, Pitt Bertram, Mcmurray John, Pfeffer Marc, Solomon Scott, Skali Hicham, Chang Sheng Nan, Lu Henri, Claggett Brian, Shin Sung-hee, Santos Angela, Inciardi Riccardo, Kosztin Annamaria, Jering Karola

You have to be authorized to contact abstract author. Please, Login
Not Available